Wedbush Upgrades Sarepta To Outperform As 'FDA Comes Up With Option C'
June 07, 2016 at 08:57 AM EDT
The FDA has requested Sarepta Therapeutics Inc (NASDAQ: SRPT) for dystrophin data in the ongoing evaluation of the eteplirsen New ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.